Spotlight Growth
No Result
View All Result
Friday, February 3, 2023
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
No Result
View All Result
No Result
View All Result
Home Bio/Med/Pharma

Creative Medical Technology Holdings, Inc. (OTCQB: CELZ) Soars 51% After Its AmnioStem Stem Cells Showed Superior Immune Modulatory Abilities Compared To Traditional

by admin
April 4, 2018
in Bio/Med/Pharma
0
Stem Cell AmnioStem Research Superior Results News

Stem Cell AmnioStem Research Superior Results News

Creative Medical Technology Holdings, Inc. (OTCQB: CELZ) is a commercial stage biotechnology company that primarily focuses on researching and developing stem cell treatments for sexual dysfunction, infertility, and related issues. Shares of the stem cell treatment company soared nearly 51% during trading on Wednesday, April 4, 2018. Over the past month, Creative Medical Technology Holdings, Inc. has seen average daily volume of 36.93 million shares. However, volume of 90.6 million shares or dollar volume of $724,822, exchanged hands during trading Wednesday.

Shares of Creative Medical Technology Holdings, Inc. surged on Wednesday, after the company announced new data showing its proprietary AmnioStem stem cell product demonstrated a superior immune modulatory ability relative to more traditional stem cells (bone marrow, adipose tissue, placental issue, etc.). The company generated the data from testing at its BioLabs facility in San Diego, California. Here is the full press release detailing of the data and what it means for the company moving forward:

Creative Medical Technology Holdings, Inc. Press Release:

PHOENIX, April 4, 2018 /PRNewswire/ — Creative Medical Technology Holdings (OTCQB: CELZ) announced today new data demonstrating superior immune modulatory ability of its AmnioStem™ stem cell product when compared head-to-head with bone marrow, adipose tissue, and placental tissue mesenchymal stem cells. The data, which was generated by the Company at its BioLabs research facility in San Diego, showed that AmnioStem™ cells were superior at suppressing production of inflammatory mediators such as TNF-alpha, interferon gamma, and interleukin-12 as compared to other stem cells.

“Control of molecules such as TNF-alpha represents a multi-billion dollar market. Currently drugs like Humira, Remicade, and Embrel, which are antibodies blocking the TNF-alpha pathway, have sales of over $30 billion per year,” said Thomas Ichim, Ph.D, Cofounder and Chief Scientific Officer of Creative Medical Technology Holdings. “Using cells as drugs represents a more viable alternative to existing approaches because the stem cells not only reduce inflammation, but also have ability to induce healing of injured tissue.”

Dr. Ichim has taken several cell therapies to FDA clearance and clinical trials. The Company is currently preparing an Investigational New Drug (IND) application with the FDA for use of its AmnioStem™ stem cell product for treatment of radiation toxicity through its neurology focused subsidiary CerebroStem LLC and its Medical Director, Santosh Kesari, MD, Ph.D, FANA, FAAN, Chair and Professor, Department of Translational Neurosciences and Neurotherapeutics, John Wayne Cancer Institute, as well as Director of Neuro-Oncology, Providence Saint John’s Health Center and leads the Pacific Neuroscience Research Center at Pacific Neuroscience Institute.

“We are extremely excited about our data, which positions Creative Medical Technology Holdings as a force in the autoimmune market. In addition to treatment of stroke and radiation toxicity, autoimmune diseases that may benefit from use of AmnioStem™ technology include Type 1 Diabetes, Rheumatoid Arthritis, Multiple Sclerosis, and Lupus,” said Timothy Warbington, President and Chief Executive Officer of Creative Medical Technology Holdings. “I am thankful for our collaborative network of scientists, scientific advisors, and intellectual property advisors, which are currently working in expanding the intellectual property portfolio surrounding this new cell type.”

The AmnioStem™ stem cell is covered by an issued US Patent that was exclusively licensed from the University of California by the Company in 2016.

About Creative Medical Technology Holdings

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company currently trading on the OTCQB under the ticker symbol CELZ. For further information about the company go to www.creativemedicaltechnology.com.

Forward-Looking Statements

OTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission’s website at www.sec.gov.

Tags: AmnioStembiopharmaceuticalsbiotechbiotechnologyclinical trialscommon stockdataemerging growthFDAinvestmentmedicalmicrocap stocksnewspharmaceuticalspublic companyresearchsmall cap companiessmall cap stockssmall capsSpotlight GrowthSpotlight Growth Stocksstem cellstreatment
  • Trending
  • Comments
  • Latest
Asure Software NASDAQ ASUR Human Capital Management HCM Industry Spotlight Growth

Asure Software (NASDAQ: ASUR) is Expanding to Meet the Rising Demand for Human Capital Management Software

September 27, 2022
OLB Group NASDAQ OLB Cuentas NASDAQ CUEN Partnership Fintech Spotlight Growth

OLB Group (NASDAQ: OLB) and Cuentas (NASDAQ: CUEN) Team Up to Bring Fintech Solutions to Over 32,000 Bodegas Across the United States

October 6, 2022
Siyata Mobile NASDAQ SYTA SYTAW SD7 VK7 Purchase Orders Spotlight Growth

New Purchase Orders for SD7 Rugged Device, VK7, and Other Accessories Boost Siyata Mobile’s Outlook (NASDAQ: SYTA)

December 14, 2021
Telcoin TEL Crypto Spotlight Growth

Telcoin (TEL) Quietly Leads a Crypto Remittance Revolution

June 15, 2021
Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

0
Safe-T SFET NASDAQ UN Presentation

Safe-T (NASDAQ: SFET) Has Been Selected to Present at the United Nations’ Office of Information and Communications Technology Event

0
Safe-T Group SFET Q4 FY 2020 Financial Results

Safe-T Group (NASDAQ: SFET) Reports Fourth Quarter and Full Year 2020 Financial Results

0
Safe-T Group NASDAQ SFET FY 2020 Prelim

Safe-T Group Ltd. (NASDAQ: SFET) Estimates Record-High Annual Revenues of Approximately $4.9 Million Representing ~50% Growth YoY 2020

0
Elys Game Technology Corp NASDAQ ELYS Completes Acquisition of Engage IT Services Spotlight Growth

Elys Game Technology Corp (NASDAQ: ELYS) Completes Acquisition of Engage IT Services, a Software Engineering and IT Development Company

February 2, 2023
Tenax Therapeutics NASDAQ TENX US Patent Levosimendan PH-HFpEF Spotlight Growth

Tenax Therapeutics (NASDAQ: TENX) Granted U.S. Patent for IV Levosimendan for Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)

February 2, 2023
Versus Systems NASDAQ VS Resolve Debt Partner AI Gamification Consumer Debt Spotlight Growth

Versus Systems (NASDAQ: VS) and Resolve Debt Partner to Integrated Generative AI and Gamification to Customer Payments and Credit Markets

February 1, 2023
Finding the Most Accurate Technical Analysis Indicator Spotlight Growth

Finding the Most Accurate Technical Analysis Indicator

January 31, 2023
ADVERTISEMENT

Recent News

Elys Game Technology Corp NASDAQ ELYS Completes Acquisition of Engage IT Services Spotlight Growth

Elys Game Technology Corp (NASDAQ: ELYS) Completes Acquisition of Engage IT Services, a Software Engineering and IT Development Company

February 2, 2023
Tenax Therapeutics NASDAQ TENX US Patent Levosimendan PH-HFpEF Spotlight Growth

Tenax Therapeutics (NASDAQ: TENX) Granted U.S. Patent for IV Levosimendan for Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)

February 2, 2023

Categories

  • Bio/Med/Pharma
  • Cannabis
  • Commodities
  • Consumer Goods
  • Crowdfunding
  • Crypto Cheat Sheets
  • Cryptocurrency
  • Earnings
  • Education
  • Entertainment
  • Financials
  • Market News
  • Opinion
  • Politics
  • Real Estate
  • Split Watch
  • Sponsored
  • Store
  • Technology
  • Uncategorized
  • Venture Capital/Private Equity (VC/PE)

Site Navigation

  • Disclosures
  • Terms Of Service
  • Privacy Policy
  • Contact Us

Copyright © 2017-2022 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

No Result
View All Result
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener

Copyright © 2017-2022 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

Newsletter Signup

Subscribe to our weekly newsletter below and never miss the latest small/micro-cap analysis and investment news from Spotlight Growth.

Enter your email address

Thanks, I’m not interested